Viewing Study NCT06651151


Ignite Creation Date: 2025-12-24 @ 11:55 PM
Ignite Modification Date: 2025-12-25 @ 9:51 PM
Study NCT ID: NCT06651151
Status: RECRUITING
Last Update Posted: 2024-10-26
First Post: 2024-10-18
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: NeoLIPA: Neoadjuvant LTX-315 in Combination with Pembrolizumab in Resectable Stage III/IV Melanoma
Sponsor: Oslo University Hospital
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module